Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Quarterly results
Director departure
Appointed director
ADOLOR CORP (ADLR) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/12/2011 8-K Quarterly results
11/10/2011 8-K Form 8-K - Current report
10/28/2011 8-K Other Events
10/24/2011 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...
Docs: "Agreement and Plan of Merger, by and among Cubist Pharmaceuticals, Inc., FRD Acquisition Corporation and Adolor Corporation",
"Amendment to Amended and Restated Rights Agreement, by and among Adolor Corporation and Broadridge Corporate Issuer Solutions, Inc.",
"CUBIST PHARMACEUTICALS TO ACQUIRE ADOLOR ACQUISITION ADDS FIRST-IN-CLASS HOSPITAL PRODUCT ENTEREG® AND PROMISING LATE-STAGE COMPOUND ADL5945 TRANSACTION EXPECTED TO BE ACCRETIVE IN 2012"
08/10/2011 8-K Form 8-K - Current report
07/27/2011 8-K Quarterly results
Docs: "ADOLOR CORPORATION REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS"
06/14/2011 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "ADOLOR CORPORATION ANNOUNCES AGREEMENT TO ACQUIRE FULL OWNERSHIP OF ENTEREG®"
05/18/2011 8-K Form 8-K - Current report
04/28/2011 8-K Form 8-K - Current report
02/23/2011 8-K Form 8-K - Current report
02/23/2011 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "ADOLOR REPORTS YEAR-END 2010 RESULTS"
01/31/2011 8-K Form 8-K - Current report
12/21/2010 8-K Form 8-K - Current report
12/21/2010 8-K Termination of a Material Definitive Agreement, Other Events
10/28/2010 8-K Form 8-K - Current report
10/20/2010 8-K Form 8-K - Current report
09/13/2010 8-K Form 8-K - Current report
07/29/2010 8-K Form 8-K - Current report
07/19/2010 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Other Events, Financial Stat...
Docs: "ADOLOR CORPORATION ANNOUNCES RESTRUCTURING"
06/22/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/21/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "ADOLOR CORPORATION PROVIDES CLINICAL UPDATE; WILL HOST CONFERENCE CALL"
05/20/2010 8-K Submission of Matters to a Vote of Security Holders
04/28/2010 8-K Quarterly results
Docs: "ADOLOR CORPORATION REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS EXTON, PA, April 28, 2010 — Adolor Corporation today reported a net loss of $9.6 million, or $ per basic and diluted share, for the three months ended March 31, 2010, compared to a net loss of $13.2 million, or $ per basic and diluted share, for the three months ended March 31, 2009. Net product sales of ENTEREG® for the three months ended March 31, 2010 were $5.3 million compared to $1.4 million for the three months ended March 31, 2009, primarily as a result of growth in the number of ordering hospitals and increased usage at ordering hospitals. Net product sales for the three months ended March 31, 2010 were recognized at the time of shipment as compared to net product sales for the three months ended March 31, 2009, which ..."
03/02/2010 8-K Form 8-K - Current report
02/25/2010 8-K Form 8-K - Current report
12/21/2009 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
10/29/2009 8-K Form 8-K - Current report
09/23/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "ADOLOR ACQUIRES RIGHTS TO CLINICAL-STAGE PRODUCT CANDIDATE FROM ELI LILLY AND COMPANY EXTON, PA, September 21, 2009 — Adolor Corporation today announced that it has acquired from Eli Lilly and Company the exclusive worldwide rights to OpRA III, a clinical-stage product candidate. OpRA III is a potent opioid receptor antagonist, with potential use in multiple therapeutic indications. Adolor intends to initially develop OpRA III to treat opioid bowel dysfunction and will initiate clinical trials of this compound for this indication in early 2010. This compound will be developed in parallel with ADL7445 as part of the Company's OBD Program. Moving forward, OpRA III will be identified as ADL5945. “OpRA III has a unique profile with the potential to address the gastrointestinal disorders associ..."
07/29/2009 8-K Form 8-K - Current report
06/09/2009 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits
Docs: "ADOLOR CORPORATION ANNOUNCES STAFF REDUCTIONS AND RESTRUCTURING"
05/14/2009 8-K Form 8-K -- Current report
04/29/2009 8-K Form 8-K -- Current report
02/25/2009 8-K Form 8-K -- Current report
02/05/2009 8-K Form 8-K -- Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy